CYP19A1 and breast cancer: Another example of UGT somatic mutations that may have an impact on drug responses relates to the treatment of estrogen receptor-positive breast cancers with antiestrogens such as tamoxifen (TAM) and aromatase inhibitors such as exemestane (EXE) [111].